Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

7.25
-1.1900-14.10%
Post-market: 7.330.0800+1.10%19:59 EDT
Volume:4.22M
Turnover:31.83M
Market Cap:750.50M
PE:-1.38
High:8.24
Open:8.23
Low:7.24
Close:8.44
Loading ...

Intellia Therapeutics Inc - Expects to Incur Charges of Approximately $8 Mln Associated With Reorganization

THOMSON REUTERS
·
10 Jan

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of Its Late-Stage Programs, Ntla-2002 and Nexiguran Ziclumeran (Nex-Z)

THOMSON REUTERS
·
10 Jan

Intellia Therapeutics Inc - Phase 3 Haelo Study Evaluating Ntla-2002 for Hae to Complete Enrollment in Second Half of 2025

THOMSON REUTERS
·
10 Jan

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

GlobeNewswire
·
10 Jan

RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

BRIEF-Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
06 Jan

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
06 Jan

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
06 Jan

Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey
·
29 Dec 2024

Here's Why We're Watching Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Simply Wall St.
·
24 Dec 2024

Intellia Crashes 60% in a Year: How Should You Play the Stock?

Zacks
·
21 Dec 2024

Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today

TIPRANKS
·
17 Dec 2024

Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey
·
12 Dec 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Dec 2024

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

Zacks
·
26 Nov 2024

NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy

Zacks
·
26 Nov 2024

Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest

TIPRANKS
·
26 Nov 2024

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

MT Newswires Live
·
26 Nov 2024

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation

MT Newswires Live
·
26 Nov 2024